Drugs / Allergovac polimerized
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02849249 Comparator | Sep 2015 → Jun 2016 | nasal cavity disorder | Roxall Medicina España S.A | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allergovac polimerized | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02849249 ↗ |
| Modality | Vaccine | “an allergy vaccine.” NCT02849249 ↗ |
| Route | Subcutaneous | “subcutaneous immunotherapy” NCT02849249 ↗ |